Preclinical data are promising but not yet clinical proof-of-concept. Monitor upcoming Phase 1 readouts for NX-1607 and NRX-0305 as next major catalysts. The absence of clinical efficacy data means current valuation relies heavily on platform optimism, leaving stock vulnerable to future setbacks.
Price Chart
Executive Summary
Nurix Therapeutics presented new preclinical data at AACR 2026 across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972, highlighting deeper biological responses and synergy over existing inhibitors. The data reinforce the company's scientific leadership in targeted protein degradation but do not include clinical efficacy results. An upcoming AACR Advances session features Nurix’s CSO discussing clinical translation of degraders.
Key Facts
- Presented preclinical data for NRX-0305 showing 142% increase in lifespan vs. 12% for approved BRAF inhibitor in melanoma brain metastasis model.
- NX-1607 demonstrated single-agent anti-tumor activity and synergy with anti-PD-1 in multiple syngeneic models; early clinical data show target engagement via pHS1 modulation.
- NRX-4972 achieved 60% survival in SCLC model vs. 0% for AURKA inhibitors alisertib and LY3295668.
- No clinical efficacy data reported; all results are preclinical or early-phase biomarker signals.
- Insider sold $124K in the past 30 days, minimal but notable given lack of commercial-stage assets.
Financial Impact
No direct financial impact from this release; pipeline remains preclinical or early-phase. Market cap remains $1.7B, reflecting high expectations for degrader platform.
Risk Factors
- High reliance on unproven degrader modality; clinical translation remains uncertain.
- Preclinical results may not replicate in human trials.
- Limited near-term revenue potential; dependent on partnerships or future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 29d ago | Insider Cluster | $25.32 $25.10 | ▼ −0.87% | ▲ +0.28% | $22.86 (−9.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.22 $27.19 | ▲ +7.81% | ▲ +6.60% | $22.86 (−9.36%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.86 (−9.00%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.86 (−9.00%) |
Aug 3, 2026 8w ago | Insider Cluster | $24.69 $25.96 | ▲ +5.14% | ▲ +5.24% | $22.86 (−7.41%) |
Jul 30, 2026 9w ago | Insider Cluster | $23.21 $25.53 | ▲ +10.00% | ▲ +6.48% | $22.86 (−1.51%) |
Jul 9, 2026 12w ago | Press Release | $23.06 $23.07 | ▲ +0.04% | ▲ +0.60% | $22.86 (−0.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $23.97 $24.69 | ▲ +3.00% | ▲ +2.07% | $22.86 (−4.63%) |
Jun 11, 2026 16w ago | Institutional Cluster | $16.98 $17.12 | ▲ +0.82% | ▲ +0.39% | $22.86 (+34.63%) |
Jun 8, 2026 16w ago | 8-K | $15.64 $17.04 | ▲ +8.95% | ▲ +6.84% | $22.86 (+46.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access